Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Indinavir
Drug ID BADD_D01150
Description A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
Indications and Usage Indinavir is an antiretroviral drug for the treatment of HIV infection.
Marketing Status approved
ATC Code J05AE02
DrugBank ID DB00224
KEGG ID D03833
MeSH ID D019469
PubChem ID 5362440
TTD Drug ID D0V7CF
NDC Product Code Not Available
UNII 5W6YA9PKKH
Synonyms Indinavir | MK-639 | MK 639 | MK639 | L-735 524 | L 735 524 | L735 524 | L-735,524 | L 735,524 | L735,524 | Crixivan | Indinavir Sulfate | Sulfate, Indinavir | Indinavir, Sulfate (1:1)
Chemical Information
Molecular Formula C36H47N5O4
CAS Registry Number 150378-17-9
SMILES CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC= C5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Shock24.06.02.002---
Sinusitis11.01.13.005; 22.07.03.007--
Skin disorder23.03.03.007---
Skin hyperpigmentation23.05.01.003--
Skin infection11.01.12.003; 23.11.04.007--
Skin odour abnormal23.03.03.012--
Sleep disorder19.02.04.001---
Somnolence17.02.04.006; 19.02.05.003--
Spleen disorder01.09.02.003---
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Swelling08.01.03.015---
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tension19.06.02.005---
Thrombocytopenia01.08.01.002---
Tremor17.01.06.002--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002---
Urinary tract disorder20.08.01.001---
Urinary tract infection11.01.14.004; 20.08.02.001--
Urine abnormality20.02.01.013---
Urticaria10.01.06.001; 23.04.02.001--
Vasculitis10.02.02.006; 24.12.04.027--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
White blood cells urine positive13.13.02.004---
Tubulointerstitial nephritis20.05.02.002---
Fat redistribution14.08.04.002---
Viral diarrhoea07.19.02.008; 11.05.04.012---
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene